Table 2.
Change in days of supply and A1C associated with SSM
| % switch to SSM | Cost and insulin use in 2018 | Change under SSM | ||||||
|---|---|---|---|---|---|---|---|---|
| Annual OOP payment ($) | Days of supply | Annual OOP payment | Days of supply* | Average A1C (%)† | ||||
| Mean (SE) ($) | % reduction | |||||||
| Subgroup 1 | White | 39.4 | 506 (11) | 231 (7) | −221 (15) | −43.7 | 0 | 0 |
| Non-White | 23.6 | 350 (47) | 170 (10) | −141 (36) | −40.3 | 0 | 0 | |
| Subgroup 2 | White | 44.8 | 672 (23) | 219 (9) | −349 (25) | −51.9 | 43 (4) | −0.19 |
| Non-White | 30.8 | 687 (4) | 179 (10) | −417 (6) | −60.7 | 40 (2) | −0.18 | |
| Subgroup 3 | White | 46.1 | 1445 (46) | 310 (5) | −1,063 (43) | −73.6 | 0 | 0 |
| Non-White | 33.1 | 1033 (1) | 330 (1) | −626 (1) | −60.6 | 0 | 0 | |
| Overall | White | 43.7 | 862 (14) | 250 (5) | −531 (14) | −61.6 | ||
| Non-White | 29.6 | 735 (17) | 241 (4) | −424 (13) | −57.7 | |||
| All | 38.3 | 827 (13) | 248 (3) | −502 (12) | −60.7 | |||
Data are means (SE) unless otherwise indicated. All costs are standardized in 2020 USD. Subgroup 1: individuals end the year in the initial phase. Subgroup 2: individuals end the year in the coverage gap. Subgroup 3: individuals end the year in the catastrophic phase.
*
Changes in days of supply were calculated based on annual OOP change and the estimated demand elasticity equation (Supplementary Table 1).
†
Changes in A1C were calculated based on change of days of supply and the equation of Schectman et al. (22).